摘要
三阴性乳腺癌(triple-negative breast cancer, TNBC)是指雌激素受体(estrogen receptor, ER)、孕激素受体(progesterone receptor, PR)及人表皮生长因子受体2 (human epidermal growth factor receptor 2, HER-2)均无表达的一类乳腺癌,与其他分子类型乳腺癌相比,TNBC对新辅助化疗(neo-adjuvant chemotherapy, NAC)的完全病理缓解率较高,效果较好。然而,超过一半的TNBC患者没达到完全病理缓解,预后较差。本文对目前三阴性乳腺癌新辅助化疗的相关文献进行了复习,对新近的研究进展进行了总结。Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2). Compared to other molecular types of breast cancer, TNBC shows a higher rate of complete pathological response and better outcomes with neoadjuvant chemotherapy (NAC). However, over half of TNBC patients do not achieve complete pathological response, resulting in poor prognosis. This article reviews the current literature on neoadjuvant chemotherapy for triple-negative breast cancer and summarizes recent research advancements.
出处
《临床医学进展》
2024年第9期66-70,共5页
Advances in Clinical Medicine
